Search

Within the framework of the Smartfarm project, AINIA has made significant strides in the efficient and sustainable production of cultivated meat, a sustainable alternative that could help meet the

In less than 3 years, the Spanish biotech company has attracted the confidence of investors and international medical institutions to complete the development of its Viva Sepscare® prototype for the

For the treatment of Borderline Personality Disorder (BPD) and Attention Deficit Hyperactivity disorder (ADHD).

The participation of two of the participating sites in Spain, Hospital Universitario de Toledo and Hospital Universitario Reina Sofía de Córdoba, has already started, and the Hospital General

The agenda also emphasizes the need to promote research and innovation, as well as public procurement tools, in the field of emerging and enabling technologies such as biotechnology.

PLG is diverse and growing, with many resources in different countries to expand our support to clients in new ways. Insourcing provides ample opportunities for improved working for both PLG and

The new Aporta platform is distinguished by offering a complete and personalized solution for flexible remuneration, allowing companies to adapt benefits to the individual needs of each employee.

The deadline for transitioning clinical trials to CTIS ends on January 30, 2025. Studies continuing beyond this date must comply with the Clinical Trials Regulation (CTR), replacing the old CTD. At

The research objectives of this collaboration include the characterization of experimental models of AD to identity those with higher physiological relevance and disease predictability.

Don't miss us at the 51st Annual Meeting of the Japanese Society of Toxicology!

All resolutions were approved. Additional resolution to increase capital for up to 100 million euros approved. 42.6867% of the issued shares represented

The objective of this study was to review the characteristics of patients admitted with septic arthritis in Spanish hospitals and to measure the associated direct medical costs.

Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study.

Meet Lifesome Therapeutics, our new member. We talked its Diego Pazos Castro, Cancer & Microbiology Research Scientist.

The top leadership team from HERA (Health Emergency Preparedness and Response), the European Commission's authority for the prevention, detection and rapid response to health emergencies in the

Mikrobiomik is working to become the first company globally to market the first biological drug based on gut microbiota in the European Union for the indication of recurrence of 'Clostridium difficile

Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre.

The event "Challenges and Opportunities for Spain in the Application of AI in Health Data Spaces," organized by AseBio together with the Ministry of Health, brought together leading organizations from